Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAKK 38/19 ctDNA- and PET-guided therapy in untreated diffuse large B-cell lymphoma
2024-516740-26-00Phase 2Authorised
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of acalabrutinib in diffuse large B-cell lymphoma (DLBCL) (4 cohorts), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoints: Progression-free survival and Complete remission rate at end of therapy. Planned start Oct 2024; status: authorised.
02
Drugs
acalabrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2024-516740-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516740-26-00.